The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first

The U.K. says its the very first country to authorize an oral antiviral medication to eliminate COVID-19. “This is necessary, because it indicates it can be administered outside of a health center setting, before COVID-19 has actually progressed to a severe stage,” said MHRA Chief Executive Dr. June Raine.

Justin Tallis/POOL/AFP by means of Getty Images

conceal caption

toggle caption

Justin Tallis/POOL/AFP by means of Getty Images

The U.K. says its the very first country to authorize an oral antiviral medication to combat COVID-19. “This is very important, since it suggests it can be administered beyond a healthcare facility setting, before COVID-19 has progressed to an extreme stage,” stated MHRA Chief Executive Dr. June Raine.

Justin Tallis/POOL/AFP via Getty Images

Mercks antiviral tablet that battles COVID-19 in adults with the disease won its first permission in the world Thursday, as the U.K.s medical regulator announced that the drug is “effective and safe at lowering the risk of hospitalization and death” in mild to moderate cases. “Today is a historic day for our country, as the U.K. is now the very first country in the world to approve an antiviral that can be taken at home for COVID-19,” Javid said. The U.K.s permission is based on medical research studies that showed the drug lowered the danger of hospitalization or death by about 50% for at-risk adults with mild to moderate COVID-19 cases.”Lagevrio is another restorative to add to our armory against COVID-19,” stated MHRA Chief Executive Dr. June Raine.

Mercks antiviral pill that battles COVID-19 in adults with the illness won its first permission in the world Thursday, as the U.K.s medical regulator revealed that the drug is “efficient and safe at minimizing the danger of hospitalization and death” in moderate to moderate cases. “Today is a historic day for our nation, as the U.K. is now the first nation in the world to approve an antiviral that can be taken at home for COVID-19,” Javid said. The U.K.s authorization is based on medical studies that revealed the drug decreased the risk of hospitalization or death by about 50% for at-risk adults with mild to moderate COVID-19 cases.

“Lagevrio is another healing to add to our armory against COVID-19,” said MHRA Chief Executive Dr. June Raine. The MHRA approved the drug for people who have moderate or mild cases of COVID-19, along with at least one risk element, such as obesity, heart illness or being 60 or older. COVID-19 rates are currently high in the U.K., with 1.1 million cases over the past 28 days– the second-most cases in the world (after the U.S.), according to Johns Hopkins University.

Leave a Reply

Your email address will not be published. Required fields are marked *